Integrating pharmacoproteomics into early-phase clinical development: State-of-the-art, challenges, and recommendations

International Journal of Molecular Sciences

Volumn 18, Issue 2, 2017, Pages

  Nandal, Savita ^a   Burt, Tal ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Burt Consultancy   (United States)

Author keywords

Biomarker; Clinical development; Clinical research; Drug development; Drug toxicity; Early phase development; First in human (FIH) studies; Omics; Pharmacodynamics (PD); Pharmacogenomics; Pharmacokinetics (PK); Pharmacometabolomics; Phase 0; Phase 1; Phase 2; Proof of concept; Proof of mechanism; Proof of principle; Proteome; Proteomics

Indexed keywords

BEVACIZUMAB; CARBON; CARBOPLATIN; CETUXIMAB; DABRAFENIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; OLAPARIB; PEGINTERFERON; PEMETREXED; RIBAVIRIN; ROFECOXIB; SORAFENIB; TELAPREVIR; TIPIFARNIB; UPROSERTIB; VORINOSTAT; BIOLOGICAL MARKER; PROTEOME;

ADENOID CYSTIC CARCINOMA; BREAST CANCER; CASTRATION RESISTANT PROSTATE CANCER; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; DISEASE COURSE; DRUG DESIGN; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; HEPATITIS C; HUMAN; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; METASTATIC BREAST CANCER; METASTATIC COLORECTAL CANCER; NON SMALL CELL LUNG CANCER; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS ADENOCARCINOMA; PHARMACOGENOMICS; PHARMACOPROTEOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN NUCLEIC ACID INTERACTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; REVIEW; SOLID TUMOR; STOMACH ADENOCARCINOMA; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; BIOLOGY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; META ANALYSIS; PROCEDURES; PROTEOMICS;

BIOMARKERS; CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; HUMANS; PROTEOME; PROTEOMICS;

EID: 85013347248     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18020448     Document Type: Review

References (108)

1. Woodcock, J. The PCAST report on pharmaceutical innovation: Implications for the FDA. Clin. Pharmacol. Ther. 2013, 94, 297–300. [CrossRef] [PubMed]
2. Food and Drug Administration (FDA). Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. Available online: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html (accessed on 12 February 2017).
3. Pammolli, F.; Magazzini, L.; Riccaboni, M. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 2011, 10, 428–438. [PubMed]
4. Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 2009, 8, 959–968. [CrossRef] [PubMed]
5. Walsh, B.T.; Seidman, S.N.; Sysko, R.; Gould, M. Placebo response in studies of major depression: Variable, substantial, and growing. JAMA 2002, 287, 1840–1847. [CrossRef] [PubMed]
6. Scannell, J.W.; Blanckley, A.; Boldon, H.; Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 2012, 11, 191–200. [PubMed]
7. How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov. 2010, 9, 203–214. [PubMed]
8. IOM. Evolution of Translational Omics: Lessons Learned and the Path Forward; The National Academies Press: Washington, DC, USA, 2012.
9. Collins, F.S. Reengineering translational science: The time is right. Sci. Transl. Med. 2011, 3, 90cm17. [CrossRef] [PubMed]
10. Wishart, D.S. Emerging applications of metabolomics in drug discovery and precision medicine. Nat. Rev. Drug Discov. 2016, 15, 473–484. [CrossRef] [PubMed]
11. Boja, E.S.; Kinsinger, C.R.; Rodriguez, H.; Srinivas, P. Integration of omics sciences to advance biology and medicine. Clin. Proteom. 2014, 11, 45. [CrossRef]
12. Russell, C.; Rahman, A.; Mohammed, A.R. Application of genomics, proteomics and metabolomics in drug discovery, development and clinic. Ther. Deliv. 2013, 4, 395–413. [CrossRef] [PubMed]
13. McShane, L.M.; Cavenagh, M.M.; Lively, T.G.; Eberhard, D.A.; Bigbee, W.L.; Williams, P.M.; Mesirov, J.P.; Polley, M.Y.; Kim, K.Y.; Tricoli, J.V.; et al. Criteria for the use of omics-based predictors in clinical trials: Explanation and elaboration. BMC Med. 2013, 11, 220. [CrossRef] [PubMed]
14. Burt, T.; Nandal, S. Pharmacometabolomics in Early-Phase Clinical Development. Clin. Transl. Sci. 2016. [CrossRef] [PubMed]
15. Burt, T.; Dhillon, S. Pharmacogenomics in early-phase clinical development. Pharmacogenomics 2013, 14, 1085–1097. [CrossRef] [PubMed]
16. Button, K.S.; Ioannidis, J.P.; Mokrysz, C.; Nosek, B.A.; Flint, J.; Robinson, E.S.; Munafo, M.R. Power failure: Why small sample size undermines the reliability of neuroscience. Nat. Rev. Neurosci. 2013, 14, 365–376. [CrossRef] [PubMed]
17. Kim, M.S.; Pinto, S.M.; Getnet, D.; Nirujogi, R.S.; Manda, S.S.; Chaerkady, R.; Madugundu, A.K.; Kelkar, D.S.; Isserlin, R.; Jain, S.; et al. A draft map of the human proteome. Nature 2014, 509, 575–581. [CrossRef] [PubMed]
18. Wasinger, V.C.; Cordwell, S.J.; Cerpa-Poljak, A.; Yan, J.X.; Gooley, A.A.; Wilkins, M.R.; Duncan, M.W.; Harris, R.; Williams, K.L.; Humphery-Smith, I. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 1995, 16, 1090–1094. [CrossRef] [PubMed]
19. Kennedy, S. The role of proteomics in toxicology: Identification of biomarkers of toxicity by protein expression analysis. Biomarkers 2002, 7, 269–290. [CrossRef] [PubMed]
20. Meister, W. Pharmacogenomics/pharmacoproteomics Europe. Pharmacogenomics 2002, 3, 449–452. [CrossRef] [PubMed]
21. Moellering, R.E.; Cravatt, B.F. How chemoproteomics can enable drug discovery and development. Chem. Biol. 2012, 19, 11–22. [CrossRef] [PubMed]
22. Rabilloud, T.; Lescuyer, P. Proteomics in mechanistic toxicology: History, concepts, achievements, caveats, and potential. Proteomics 2015, 15, 1051–1074. [CrossRef] [PubMed]
23. Li, D.; Chan, D.W. Proteomic cancer biomarkers from discovery to approval: It’s worth the effort. Expert Rev. Proteom. 2014, 11, 135–136. [CrossRef] [PubMed]
24. Hartley, H. Origin of the word “protein”. Nature 1951, 168, 244. [CrossRef] [PubMed]
25. Thomson, J.J. Bakerian Lecture: Rays of Positive Electricity. Proc. R. Soc. Lond. Ser. A 1913, 89, 1–20. [CrossRef]
26. Coons, A.H.; Creech, H.J.; Jones, R.N. Immunological Properties of an Antibody Containing a Fluorescent Group. Exp. Biol. Med. 1941, 47, 200–202. [CrossRef]
27. Horning, M.G.; Knox, K.L.; Dalgliesh, C.E.; Horning, E.C. Gas-liquid chromatographic study and estimation of several urinary aromatic acids. Anal. Biochem. 1966, 17, 244–257. [CrossRef]
28. Ryhage, R.; Stenhagen, E. Mass spectrometry in lipid research. J. Lipid Res. 1960, 1, 361–390. [PubMed]
29. Engvall, E.; Perlmann, P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 1971, 8, 871–874. [CrossRef]
30. Van Weemen, B.K.; Schuurs, A.H. Immunoassay using antigen-enzyme conjugates. FEBS Lett. 1971, 15, 232–236. [CrossRef]
31. O’Farrell, P.H. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 1975, 250, 4007–4021. [PubMed]
32. Klose, J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 1975, 26, 231–243. [PubMed]
33. Scheele, G.A. Two-dimensional gel analysis of soluble proteins. Charaterization of guinea pig exocrine pancreatic proteins. J. Biol. Chem. 1975, 250, 5375–5385. [PubMed]
34. Games, D.E.; Alcock, N.J.; van der Greef, J.; Nyssen, L.M.; Maarse, H.; Ten, M.C.; de Brauw, N. Analysis of pepper and capsicum oleoresins by high-performance liquid chromatography—Mass spectrometry and field desorption mass spectrometry. J. Chromatogr. A 1984, 294, 269–279. [CrossRef]
35. Van der Greef, J.; Tas, A.C.; Bouwman, J.; Ten Noever de Brauw, M.C.; Schreurs, W.H.P. Evaluation of field-desorption and fast atom-bombardment mass spectrometric profiles by pattern recognition techniques. Anal. Chim. Acta 1983, 150, 45–52. [CrossRef]
36. Bain, J.R.; Stevens, R.D.; Wenner, B.R.; Ilkayeva, O.; Muoio, D.M.; Newgard, C.B. Metabolomics applied to diabetes research: Moving from information to knowledge. Diabetes 2009, 58, 2429–2443. [CrossRef] [PubMed]
37. Van der Greef, J.; Hankemeier, T.; McBurney, R.N. Metabolomics-based systems biology and personalized medicine: Moving towards n = 1 clinical trials? Pharmacogenomics 2006, 7, 1087–1094. [CrossRef] [PubMed]
38. Anderson, N.L.; Edwards, J.J.; Giometti, C.S. High resolution two dimensional electrophoretic mapping of human proteins. In Proceedings of the Electrophoresis’79, Munich, Germany, October 15–17; Radola, B.J., Ed.; Walter de Gruyter: Berlin, Germany, 1980.
39. Feuerstein, N.; Cooper, H.L. Rapid phosphorylation-dephosphorylation of specific proteins induced by phorbol ester in HL-60 cells. Further characterization of the phosphorylation of 17-kilodalton and 27-kilodalton proteins in myeloid leukemic cells and human monocytes. J. Biol. Chem. 1984, 259, 2782–2788. [PubMed]
40. 2+-dependent protein kinase activity and protein phosphorylation patterns in the differentiation of human promyelocytic leukemia cell line HL-60. Cancer Res. 1985, 45, 5159–5164. [PubMed]
41. Aebersold, R.H.; Leavitt, J.; Saavedra, R.A.; Hood, L.E.; Kent, S.B. Internal amino acid sequence analysis of proteins separated by one- or two-dimensional gel electrophoresis after in situ protease digestion on nitrocellulose. Proc. Natl. Acad. Sci. USA 1987, 84, 6970–6974. [CrossRef] [PubMed]
42. Aebersold, R.H.; Teplow, D.B.; Hood, L.E.; Kent, S.B. Electroblotting onto activated glass. High efficiency preparation of proteins from analytical sodium dodecyl sulfate-polyacrylamide gels for direct sequence analysis. J. Biol. Chem. 1986, 261, 4229–4238. [PubMed]
43. Fenn, J.B.; Mann, M.; Meng, C.K.; Wong, S.F.; Whitehouse, C.M. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989, 246, 64–71. [CrossRef] [PubMed]
44. Karas, M.; Hillenkamp, F. Laser desorption ionization of proteins with molecular mass exceeding 10000 daltons. Anal. Chem. 1988, 60, 2299–2301. [CrossRef] [PubMed]
45. Hutchens, T.W.; Yip, T.-T. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun. Mass Spectrom. 1993, 7, 576–580. [CrossRef]
46. Wilkins, M.R.; Pasquali, C.; Appel, R.D.; Ou, K.; Golaz, O.; Sanchez, J.C.; Yan, J.X.; Gooley, A.A.; Hughes, G.; Humphery-Smith, I.; et al. From proteins to proteomes: Large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology 1996, 14, 61–65. [CrossRef] [PubMed]
47. Wilkins, M.R.; Sanchez, J.C.; Gooley, A.A.; Appel, R.D.; Humphery-Smith, I.; Hochstrasser, D.F.; Williams, K.L. Progress with proteome projects: Why all proteins expressed by a genome should be identified and how to do it. Biotechnol. Genet. Eng. Rev. 1996, 13, 19–50. [CrossRef] [PubMed]
48. Gygi, S.P. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 1999, 17, 994–999. [CrossRef] [PubMed]
49. Tunon, J.; Martin-Ventura, J.L.; Blanco-Colio, L.M.; Lorenzo, O.; Lopez, J.A.; Egido, J. Proteomic strategies in the search of new biomarkers in atherothrombosis. J. Am. Coll. Cardiol. 2010, 55, 2009–2016. [CrossRef] [PubMed]
50. Ong, S.E. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteom. 2002, 1, 376–386. [CrossRef]
51. Blagoev, B. A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling. Nat. Biotechnol. 2003, 21, 315–318. [CrossRef] [PubMed]
52. Ross, P.L.; Huang, Y.N.; Marchese, J.N.; Williamson, B.; Parker, K.; Hattan, S.; Khainovski, N.; Pillai, S.; Dey, S.; Daniels, S.; et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteom. 2004, 3, 1154–1169. [CrossRef] [PubMed]
53. Burt, T.; John, C.S.; Ruckle, J.L.; Vuong, L.T. Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: A range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans—A practical guide. Expert Opin. Drug Deliv. 2016, 1–16. [CrossRef] [PubMed]
54. Coleman, H.N.; Greenfield, W.W.; Stratton, S.L.; Vaughn, R.; Kieber, A.; Moerman-Herzog, A.M.; Spencer, H.J.; Hitt, W.C.; Quick, C.M.; Hutchins, L.F.; et al. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer Immunol. Immunother. 2016, 65, 563–573. [CrossRef] [PubMed]
55. Cheraghchi-Bashi, A.; Parker, C.A.; Curry, E.; Salazar, J.F.; Gungor, H.; Saleem, A.; Cunnea, P.; Rama, N.; Salinas, C.; Mills, G.B.; et al. A putative biomarker signature for clinically effective AKT inhibition: Correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway. Oncotarget 2015, 6, 41736–41749. [PubMed]
56. Corcoran, R.B.; Atreya, C.E.; Falchook, G.S.; Kwak, E.L.; Ryan, D.P.; Bendell, J.C.; Hamid, O.; Messersmith, W.A.; Daud, A.; Kurzrock, R.; et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J. Clin. Oncol. 2015, 33, 4023–4031. [CrossRef] [PubMed]
57. Buscail, L.; Bournet, B.; Vernejoul, F.; Cambois, G.; Lulka, H.; Hanoun, N.; Dufresne, M.; Meulle, A.; Vignolle-Vidoni, A.; Ligat, L.; et al. First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: Safety, biodistribution, and preliminary clinical findings. Mol. Ther. 2015, 23, 779–789. [CrossRef] [PubMed]
58. Hare, B.J.; Haseltine, E.; Fleming, M.; Chelsky, D.; McIntosh, L.; Allard, R.; Botfield, M. A signature for immune response correlates with HCV treatment outcome in Caucasian subjects. J. Proteom. 2015, 116, 59–67. [CrossRef] [PubMed]
59. Lee, J.M.; Hays, J.L.; Annunziata, C.M.; Noonan, A.M.; Minasian, L.; Zujewski, J.A.; Yu, M.; Gordon, N.; Ji, J.; sSissung, T.M.; et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J. Natl. Cancer Inst. 2014, 106, dju089. [CrossRef] [PubMed]
60. Holloway, M.; McClanahan, P.; Meyer, K.; et al. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cancer Med. 2014, 3, 572–579. [CrossRef] [PubMed]
61. Maitland, M.L.; Levine, M.R.; Lacouture, M.E.; Wroblewski, K.E.; Chung, C.H.; Gordon, I.O.; Szeto, L.; Ratko, G.; Soltani, K.; Kozloff, M.F.; et al. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer 2014, 14, 5. [CrossRef] [PubMed]
62. Templeton, A.J.; Dutoit, V.; Cathomas, R.; Rothermundt, C.; Bartschi, D.; Droge, C.; Gautschi, O.; Borner, M.; Fechter, E.; Stenner, F.; et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur. Urol. 2013, 64, 150–158. [CrossRef] [PubMed]
63. Azad, N.; Yu, M.; Davidson, B.; Choyke, P.; Chen, C.C.; Wood, B.J.; Venkatesan, A.; Henning, R.; Calvo, K.; Minasian, L.; et al. Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort. Mol. Cell. Proteom. 2013, 12, 1621–1631. [CrossRef] [PubMed]
64. Stinchcombe, T.E.; Roder, J.; Peterman, A.H.; Grigorieva, J.; Lee, C.B.; Moore, D.T.; Socinski, M.A. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer. J. Thorac. Oncol. 2013, 8, 443–451. [CrossRef] [PubMed]
65. Akerley, W.; Boucher, K.; Rich, N.; Egbert, L.; Harker, G.; Bylund, J.; van Duren, T.; Reddy, C. A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer 2013, 79, 307–311. [CrossRef] [PubMed]
66. Chinnaiyan, P.; Chowdhary, S.; Potthast, L.; Prabhu, A.; Tsai, Y.Y.; Sarcar, B.; Kahali, S.; Brem, S.; Yu, H.M.; Rojiani, A.; et al. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro Oncol. 2012, 14, 93–100. [CrossRef] [PubMed]
67. Jensen, A.D.; Nikoghosyan, A.; Hinke, A.; Debus, J.; Munter, M.W. Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux(R) and particle therapy]. BMC Cancer 2011, 11, 70. [CrossRef] [PubMed]
68. Dalenc, F.; Doisneau-Sixou, S.F.; Allal, B.C.; Marsili, S.; Lauwers-Cances, V.; Chaoui, K.; Schiltz, O.; Monsarrat, B.; Filleron, T.; Renee, N.; et al. Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: A negative phase II and screening of potential therapeutic markers by proteomic analysis. Clin. Cancer Res. 2010, 16, 1264–1271. [CrossRef] [PubMed]
69. Tabernero, J.; Cervantes, A.; Rivera, F.; Martinelli, E.; Rojo, F.; von Heydebreck, A.; Macarulla, T.; Rodriguez-Braun, E.; Eugenia Vega-Villegas, M.; Senger, S.; et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: Biomarker analysis of a phase I dose-escalation study. J. Clin. Oncol. 2010, 28, 1181–1189. [CrossRef] [PubMed]
70. Debucquoy, A.; Haustermans, K.; Daemen, A.; Aydin, S.; Libbrecht, L.; Gevaert, O.; de Moor, B.; Tejpar, S.; McBride, W.H.; Penninckx, F.; et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J. Clin. Oncol. 2009, 27, 2751–2757. [CrossRef] [PubMed]
71. Schilder, R.J.; Pathak, H.B.; Lokshin, A.E.; Holloway, R.W.; Alvarez, R.D.; Aghajanian, C.; Min, H.; Devarajan, K.; Ross, E.; Drescher, C.W.; et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol. Oncol. 2009, 113, 21–27. [CrossRef] [PubMed]
72. O’Byrne, K.J.; Danson, S.; Dunlop, D.; Botwood, N.; Taguchi, F.; Carbone, D.; Ranson, M. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J. Clin. Oncol. 2007, 25, 3266–3273. [CrossRef] [PubMed]
73. Posadas, E.M.; Kwitkowski, V.; Kotz, H.L.; Espina, V.; Minasian, L.; Tchabo, N.; Premkumar, A.; Hussain, M.M.; Chang, R.; Steinberg, S.M.; et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: A phase II clinical study with proteomic profiling. Cancer 2007, 110, 309–317. [CrossRef] [PubMed]
74. Dragovich, T.; McCoy, S.; Fenoglio-Preiser, C.M.; Wang, J.; Benedetti, J.K.; Baker, A.F.; Hackett, C.B.; Urba, S.G.; Zaner, K.S.; Blanke, C.D.; et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J. Clin. Oncol. 2006, 24, 4922–4927. [CrossRef] [PubMed]
75. Shusta, E.V. Blood-brain barrier genomics, proteomics, and new transporter discovery. NeuroRx 2005, 2, 151–161. [CrossRef] [PubMed]
76. Boessen, R.; Heerspink, H.J.; de Zeeuw, D.; Grobbee, D.E.; Groenwold, R.H.; Roes, K.C. Improving clinical trial efficiency by biomarker-guided patient selection. Trials 2014, 15, 103. [CrossRef] [PubMed]
77. Goldstein, R.L.; Yang, S.N.; Taldone, T.; Chang, B.; Gerecitano, J.; Elenitoba-Johnson, K.; Shaknovich, R.; Tam, W.; Leonard, J.P.; Chiosis, G.; et al. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. J. Clin. Investig. 2015, 125, 4559–4571. [CrossRef] [PubMed]
78. Food and Drug Administration (FDA). Draft Guidance: Guidance for Industry. Expedited Programs for Serious Conditions—Drugs and Biologics; Food and Drug Administration: Silver Spring, MD, USA, 2013.
79. Riveros, C.; Dechartres, A.; Perrodeau, E.; Haneef, R.; Boutron, I.; Ravaud, P. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PLoS Med. 2013, 10, e1001566. [CrossRef] [PubMed]
80. Diamandis, E.P. Cancer biomarkers: Can we turn recent failures into success? J. Natl. Cancer Inst. 2010, 102, 1462–1467. [CrossRef] [PubMed]
81. Han, Y.; Wang, X.J. Serum proteomics in biomedical research: A systematic review. Appl. Biochem. Biotechnol. 2013, 170, 774–786. [CrossRef] [PubMed]
82. Pavlou, M.P.; Diamandis, E.P.; Blasutig, I.M. The long journey of cancer biomarkers from the bench to the clinic. Clin. Chem. 2013, 59, 147–157. [CrossRef] [PubMed]
83. D’Abramo, F.; Schildmann, J.; Vollmann, J. Research participants’ perceptions and views on consent for biobank research: A review of empirical data and ethical analysis. BMC Med. Ethics 2015, 16, 60. [CrossRef] [PubMed]
84. Guo, Y.; Graber, A.; McBurney, R.N.; Balasubramanian, R. Sample size and statistical power considerations in high-dimensionality data settings: A comparative study of classification algorithms. BMC Bioinf. 2010, 11, 447. [CrossRef] [PubMed]
85. Kummar, S.; Williams, P.M.; Lih, C.J.; Polley, E.C.; Chen, A.P.; Rubinstein, L.V.; Zhao, Y.; Simon, R.M.; Conley, B.A.; Doroshow, J.H. Application of molecular profiling in clinical trials for advanced metastatic cancers. J. Natl. Cancer Inst. 2015, 107, djv003. [CrossRef] [PubMed]
86. Freidlin, B.; McShane, L.M.; Polley, M.-Y.C.; Korn, E.L. Randomized Phase II Trial Designs with Biomarkers. J. Clin. Oncol. 2012, 30, 3304–3309. [CrossRef] [PubMed]
87. Edelman, M.J.; Schneider, C.P.; Tsai, C.M.; Kim, H.T.; Quoix, E.; Luft, A.V.; Kaleta, R.; Mukhopadhyay, P.; Trifan, O.C.; Whitaker, L.; et al. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by β-3 tubulin status. J. Clin. Oncol. 2013, 31, 1990–1996. [CrossRef] [PubMed]
88. Seymour, L.; Ivy, S.P.; Sargent, D.; Spriggs, D.; Baker, L.; Rubinstein, L.; Ratain, M.J.; Le Blanc, M.; Stewart, D.; Crowley, J.; et al. The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clin. Cancer Res. 2010, 16, 1764–1769. [CrossRef] [PubMed]
89. Freidlin, B.; Korn, E.L. Biomarker enrichment strategies: Matching trial design to biomarker credentials. Nat. Rev. Clin. Oncol. 2014, 11, 81–90. [CrossRef] [PubMed]
90. Mandrekar, S.J.; Sargent, D.J. Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges. J. Clin. Oncol. 2009, 27, 4027–4034. [CrossRef] [PubMed]
91. Burbaum, J.; Tobal, G.M. Proteomics in drug discovery. Curr. Opin. Chem. Biol. 2002, 6, 427–433. [CrossRef]
92. McDonald, W.H.; Ohi, R.; Miyamoto, D.T.; Mitchison, T.J.; Yates III, J.R. Comparison of three directly coupled HPLC MS/MS strategies for identification of proteins from complex mixtures: Single-dimension LC-MS/MS, 2-phase MudPIT, and 3-phase MudPIT. Int. J. Mass Spectrom. 2002, 219, 245–251. [CrossRef]
93. Washburn, M.P.; Wolters, D.; Yates, J.R. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 2001, 19, 242–247. [CrossRef] [PubMed]
94. Mann, M. Functional and quantitative proteomics using SILAC. Nat. Rev. Mol. Cell Biol. 2006, 7, 952–958. [CrossRef] [PubMed]
95. Yang, Z.; Chevolot, Y.; Ataman-Önal, Y.; Choquet-Kastylevsky, G.; Souteyrand, E.; Laurenceau, E. Cancer biomarkers detection using 3D microstructured protein chip: Implementation of customized multiplex immunoassay. Sens. Actuators B Chem. 2012, 175, 22–28. [CrossRef]
96. Wiedl, T.; Arni, S.; Roschitzki, B.; Grossmann, J.; Collaud, S.; Soltermann, A.; Hillinger, S.; Aebersold, R.; Weder, W. Activity-based proteomics: Identification of ABHD11 and ESD activities as potential biomarkers for human lung adenocarcinoma. J. Proteom. 2011, 74, 1884–1894. [CrossRef] [PubMed]
97. Karas, M.; Bachmann, D.; Bahr, U.; Hillenkamp, F. Matrix-assisted ultraviolet laser desorption of non-volatile compounds. Int. J. Mass Spectrom. Ion Process. 1987, 78, 53–68. [CrossRef]
98. Ho, C.S.; Lam, C.W.; Chan, M.H.; Cheung, R.C.; Law, L.K.; Lit, L.C.; Ng, K.F.; Suen, M.W.; Tai, H.L. Electrospray ionisation mass spectrometry: Principles and clinical applications. Clin. Biochem. 2003, 24, 3–12.
99. Kim, H.J.; Kang, U.B.; Lee, H.; Jung, J.H.; Lee, S.T.; Yu, M.H.; Kim, H.; Lee, C. Profiling of differentially expressed proteins in stage IV colorectal cancers with good and poor outcomes. J. Proteom. 2012, 75, 2983–2997. [CrossRef] [PubMed]
100. Hall, D.A.; Ptacek, J.; Snyder, M. Protein microarray technology. Mech. Ageing Dev. 2007, 128, 161–167. [CrossRef] [PubMed]
101. Hoogenboom, H.R.; de Bruine, A.P.; Hufton, S.E.; Hoet, R.M.; Arends, J.W.; Roovers, R.C. Antibody phage display technology and its applications. Immunotechnology 1998, 4, 1–20. [CrossRef]
102. He, M.; Taussig, M.J. Ribosome display: Cell-free protein display technology. Brief. Funct. Genom. Proteom. 2002, 1, 204–212. [CrossRef]
103. Kramer, H.B.; Nicholson, B.; Kessler, B.M.; Altun, M. Detection of ubiquitin-proteasome enzymatic activities in cells: Application of activity-based probes to inhibitor development. Biochim. Biophys. Acta 2012, 1823, 2029–2037. [CrossRef] [PubMed]
104. Fonovic, M.; Bogyo, M. Activity based probes for proteases: Applications to biomarker discovery, molecular imaging and drug screening. Curr. Pharm. Des. 2007, 13, 253–261. [CrossRef] [PubMed]
105. Fonovic, M.; Bogyo, M. Activity-based probes as a tool for functional proteomic analysis of proteases. Expert Rev. Proteom. 2008, 5, 721–730. [CrossRef] [PubMed]
106. Pichler, C.M.; Krysiak, J.; Breinbauer, R. Target identification of covalently binding drugs by activity-based protein profiling (ABPP). Bioorg. Med. Chem. 2016, 24, 3291–3303. [CrossRef] [PubMed]
107. Paweletz, C.P.; Charboneau, L.; Bichsel, V.E.; Simone, N.L.; Chen, T.; Gillespie, J.W.; Emmert-Buck, M.R.; Roth, M.J.; Petricoin, E.F.; Liotta, L.A. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001, 20, 1981–1989. [CrossRef] [PubMed]
108. Boellner, S.; Becker, K.F. Reverse Phase Protein Arrays—Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use. Microarrays 2015, 4, 98–114. [CrossRef] [PubMed]